Andrew Morris
Concepts (451)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lysophospholipids | 15 | 2016 | 34 | 1.800 |
Why?
| Polyisoprenyl Phosphates | 4 | 2014 | 13 | 1.030 |
Why?
| Polychlorinated Biphenyls | 8 | 2018 | 25 | 0.970 |
Why?
| Streptomyces | 9 | 2016 | 10 | 0.860 |
Why?
| Lipid Metabolism | 3 | 2013 | 175 | 0.840 |
Why?
| Sphingosine | 9 | 2015 | 26 | 0.810 |
Why?
| Phosphatidate Phosphatase | 6 | 2018 | 11 | 0.670 |
Why?
| Phosphoric Monoester Hydrolases | 5 | 2015 | 22 | 0.660 |
Why?
| Adipogenesis | 3 | 2018 | 51 | 0.620 |
Why?
| Ceramides | 6 | 2014 | 28 | 0.590 |
Why?
| Animals | 44 | 2018 | 13187 | 0.500 |
Why?
| Phosphoric Diester Hydrolases | 6 | 2016 | 30 | 0.500 |
Why?
| Mice | 31 | 2018 | 5739 | 0.490 |
Why?
| Protein Prenylation | 2 | 2013 | 5 | 0.470 |
Why?
| Farnesol | 1 | 2013 | 4 | 0.460 |
Why?
| Mevalonic Acid | 1 | 2013 | 5 | 0.460 |
Why?
| Diterpenes | 1 | 2013 | 31 | 0.450 |
Why?
| Phosphotransferases (Alcohol Group Acceptor) | 5 | 2014 | 21 | 0.450 |
Why?
| Sesquiterpenes | 2 | 2013 | 90 | 0.430 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 138 | 0.400 |
Why?
| Environmental Pollutants | 4 | 2018 | 91 | 0.400 |
Why?
| Adipocytes | 4 | 2018 | 121 | 0.400 |
Why?
| Enzyme Inhibitors | 5 | 2015 | 391 | 0.390 |
Why?
| Sphingolipids | 3 | 2018 | 15 | 0.390 |
Why?
| Glucose | 4 | 2015 | 344 | 0.390 |
Why?
| Signal Transduction | 10 | 2016 | 1618 | 0.370 |
Why?
| Nuclear Localization Signals | 1 | 2010 | 6 | 0.370 |
Why?
| Mice, Inbred C57BL | 16 | 2016 | 1816 | 0.370 |
Why?
| Phosphatidic Acids | 1 | 2010 | 8 | 0.370 |
Why?
| Molecular Structure | 12 | 2017 | 297 | 0.350 |
Why?
| Endoplasmic Reticulum | 1 | 2010 | 108 | 0.330 |
Why?
| Antifungal Agents | 3 | 2016 | 339 | 0.330 |
Why?
| Nuclear Proteins | 1 | 2010 | 242 | 0.320 |
Why?
| Membrane Proteins | 3 | 2015 | 341 | 0.320 |
Why?
| Homeostasis | 3 | 2015 | 200 | 0.320 |
Why?
| Diet, High-Fat | 4 | 2015 | 222 | 0.310 |
Why?
| Cell Movement | 6 | 2013 | 247 | 0.290 |
Why?
| Methylamines | 2 | 2018 | 17 | 0.290 |
Why?
| Oxazoles | 2 | 2016 | 8 | 0.290 |
Why?
| Anti-Bacterial Agents | 4 | 2016 | 744 | 0.280 |
Why?
| Oxidative Stress | 5 | 2015 | 770 | 0.280 |
Why?
| Glycosides | 2 | 2016 | 17 | 0.270 |
Why?
| Oligopeptides | 2 | 2016 | 89 | 0.270 |
Why?
| Neuroprotective Agents | 2 | 2016 | 105 | 0.260 |
Why?
| Multidrug Resistance-Associated Proteins | 2 | 2015 | 17 | 0.260 |
Why?
| Liver | 4 | 2016 | 1115 | 0.260 |
Why?
| Glutathione | 3 | 2015 | 295 | 0.260 |
Why?
| S-Adenosylmethionine | 2 | 2016 | 63 | 0.250 |
Why?
| Drug Design | 4 | 2015 | 120 | 0.250 |
Why?
| Antineoplastic Agents | 1 | 2013 | 1171 | 0.250 |
Why?
| Antibiotics, Antineoplastic | 2 | 2015 | 78 | 0.250 |
Why?
| Obesity | 5 | 2018 | 1113 | 0.240 |
Why?
| Aminoglycosides | 2 | 2015 | 18 | 0.240 |
Why?
| Phenols | 2 | 2016 | 113 | 0.230 |
Why?
| Peptides, Cyclic | 2 | 2014 | 41 | 0.230 |
Why?
| Cells, Cultured | 6 | 2013 | 1573 | 0.230 |
Why?
| Sphingomyelin Phosphodiesterase | 2 | 2014 | 10 | 0.230 |
Why?
| Doxorubicin | 2 | 2015 | 233 | 0.230 |
Why?
| Endothelial Cells | 4 | 2014 | 269 | 0.220 |
Why?
| Neoplasms | 1 | 2013 | 1235 | 0.220 |
Why?
| Stem Cells | 2 | 2015 | 171 | 0.220 |
Why?
| Focal Adhesions | 2 | 2013 | 14 | 0.210 |
Why?
| Atherosclerosis | 2 | 2016 | 214 | 0.210 |
Why?
| Diet | 2 | 2018 | 566 | 0.200 |
Why?
| Cell Line, Tumor | 7 | 2013 | 1403 | 0.200 |
Why?
| Mice, Knockout | 8 | 2015 | 841 | 0.190 |
Why?
| Humans | 31 | 2018 | 49974 | 0.180 |
Why?
| Myocardial Infarction | 2 | 2015 | 389 | 0.180 |
Why?
| Blood Platelets | 2 | 2012 | 245 | 0.170 |
Why?
| HeLa Cells | 4 | 2016 | 250 | 0.170 |
Why?
| Glucosides | 2 | 2015 | 16 | 0.160 |
Why?
| Peptides | 2 | 2016 | 223 | 0.160 |
Why?
| Insulin Resistance | 3 | 2015 | 264 | 0.160 |
Why?
| Receptors, Aryl Hydrocarbon | 2 | 2015 | 25 | 0.160 |
Why?
| Hematopoietic Stem Cell Mobilization | 2 | 2015 | 57 | 0.150 |
Why?
| Dioxins | 1 | 2018 | 9 | 0.150 |
Why?
| Myocardium | 3 | 2015 | 436 | 0.150 |
Why?
| Up-Regulation | 3 | 2016 | 452 | 0.150 |
Why?
| Mutation | 2 | 2013 | 1294 | 0.150 |
Why?
| Bone Marrow Cells | 2 | 2015 | 191 | 0.150 |
Why?
| Curcumin | 1 | 2017 | 16 | 0.150 |
Why?
| Deuterium | 2 | 2016 | 42 | 0.140 |
Why?
| NF-E2-Related Factor 2 | 3 | 2013 | 41 | 0.140 |
Why?
| Ethers | 1 | 2016 | 8 | 0.140 |
Why?
| Cell Nucleus | 2 | 2015 | 183 | 0.140 |
Why?
| Naphthoquinones | 2 | 2013 | 10 | 0.140 |
Why?
| Obesity, Morbid | 1 | 2018 | 78 | 0.140 |
Why?
| Oxygenases | 1 | 2016 | 14 | 0.140 |
Why?
| Choline | 1 | 2016 | 61 | 0.130 |
Why?
| Steroids | 1 | 2016 | 57 | 0.130 |
Why?
| HEK293 Cells | 5 | 2016 | 222 | 0.130 |
Why?
| Durapatite | 1 | 2015 | 24 | 0.130 |
Why?
| Bile Acids and Salts | 1 | 2016 | 75 | 0.130 |
Why?
| Nuclear Magnetic Resonance, Biomolecular | 4 | 2017 | 30 | 0.130 |
Why?
| Terphenyl Compounds | 1 | 2015 | 1 | 0.130 |
Why?
| Hexuronic Acids | 1 | 2015 | 5 | 0.130 |
Why?
| Male | 15 | 2018 | 25241 | 0.130 |
Why?
| Dietary Fats | 2 | 2016 | 133 | 0.130 |
Why?
| Drug Carriers | 1 | 2015 | 67 | 0.130 |
Why?
| Uridine | 1 | 2015 | 5 | 0.130 |
Why?
| Lipoprotein Lipase | 1 | 2015 | 12 | 0.130 |
Why?
| Serine C-Palmitoyltransferase | 1 | 2015 | 6 | 0.130 |
Why?
| Hematopoietic Stem Cells | 2 | 2014 | 184 | 0.130 |
Why?
| Tandem Mass Spectrometry | 2 | 2013 | 236 | 0.130 |
Why?
| Multigene Family | 1 | 2015 | 56 | 0.130 |
Why?
| Vancomycin | 1 | 2015 | 81 | 0.130 |
Why?
| Glucuronides | 1 | 2015 | 45 | 0.130 |
Why?
| Myocytes, Smooth Muscle | 2 | 2012 | 86 | 0.120 |
Why?
| Drug Resistance, Bacterial | 1 | 2015 | 71 | 0.120 |
Why?
| Pyrrolidonecarboxylic Acid | 1 | 2014 | 1 | 0.120 |
Why?
| Thiazolidines | 1 | 2014 | 5 | 0.120 |
Why?
| RNA, Messenger | 3 | 2014 | 1105 | 0.120 |
Why?
| Streptomyces antibioticus | 1 | 2014 | 1 | 0.120 |
Why?
| Weight Loss | 2 | 2015 | 237 | 0.120 |
Why?
| Receptors, Steroid | 1 | 2014 | 19 | 0.120 |
Why?
| Osteomyelitis | 1 | 2015 | 126 | 0.120 |
Why?
| Antioxidants | 2 | 2013 | 249 | 0.120 |
Why?
| Glycosyltransferases | 1 | 2014 | 10 | 0.120 |
Why?
| Carbohydrate Metabolism | 1 | 2014 | 26 | 0.120 |
Why?
| Macrophages | 3 | 2014 | 363 | 0.120 |
Why?
| Methionine Adenosyltransferase | 1 | 2014 | 19 | 0.120 |
Why?
| Nucleotides | 1 | 2014 | 23 | 0.120 |
Why?
| Archaeal Proteins | 1 | 2014 | 15 | 0.120 |
Why?
| Cell Proliferation | 3 | 2013 | 1007 | 0.120 |
Why?
| Capillary Permeability | 1 | 2014 | 35 | 0.120 |
Why?
| Sulfolobus solfataricus | 1 | 2014 | 21 | 0.120 |
Why?
| Amines | 1 | 2014 | 40 | 0.120 |
Why?
| Macrolides | 1 | 2013 | 16 | 0.120 |
Why?
| Enzymes | 1 | 2013 | 28 | 0.120 |
Why?
| Rifabutin | 1 | 2013 | 5 | 0.110 |
Why?
| Pyrones | 1 | 2013 | 8 | 0.110 |
Why?
| Isocitrate Dehydrogenase | 1 | 2013 | 17 | 0.110 |
Why?
| Apolipoproteins E | 1 | 2014 | 56 | 0.110 |
Why?
| Benzoxazoles | 1 | 2013 | 11 | 0.110 |
Why?
| Hydroxymethylglutaryl CoA Reductases | 1 | 2013 | 9 | 0.110 |
Why?
| Actinobacteria | 1 | 2013 | 8 | 0.110 |
Why?
| Phosphodiesterase Inhibitors | 1 | 2013 | 23 | 0.110 |
Why?
| Chromans | 1 | 2013 | 37 | 0.110 |
Why?
| Benzhydryl Compounds | 1 | 2014 | 67 | 0.110 |
Why?
| Rhamnose | 1 | 2013 | 5 | 0.110 |
Why?
| Half-Life | 1 | 2013 | 84 | 0.110 |
Why?
| Tea | 1 | 2013 | 30 | 0.110 |
Why?
| Inflammation Mediators | 2 | 2014 | 112 | 0.110 |
Why?
| Methyltransferases | 1 | 2013 | 27 | 0.110 |
Why?
| Tissue Distribution | 1 | 2013 | 163 | 0.110 |
Why?
| Stilbenes | 1 | 2013 | 62 | 0.110 |
Why?
| Cysteine | 1 | 2013 | 50 | 0.110 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2014 | 181 | 0.110 |
Why?
| Molecular Sequence Data | 2 | 2015 | 792 | 0.110 |
Why?
| Insulin | 2 | 2013 | 457 | 0.110 |
Why?
| Thionucleosides | 1 | 2012 | 2 | 0.110 |
Why?
| Antimicrobial Cationic Peptides | 1 | 2013 | 28 | 0.110 |
Why?
| Ubiquitination | 1 | 2013 | 43 | 0.110 |
Why?
| Adenosine Monophosphate | 1 | 2012 | 15 | 0.110 |
Why?
| Anion Transport Proteins | 1 | 2012 | 4 | 0.110 |
Why?
| Central Nervous System Neoplasms | 1 | 2013 | 63 | 0.110 |
Why?
| Receptors, Lipoprotein | 1 | 2012 | 7 | 0.110 |
Why?
| Carotid Artery Injuries | 1 | 2012 | 13 | 0.110 |
Why?
| Glioma | 1 | 2013 | 79 | 0.110 |
Why?
| Lymph | 1 | 2012 | 19 | 0.110 |
Why?
| Ubiquitin-Protein Ligases | 1 | 2013 | 92 | 0.110 |
Why?
| Diacylglycerol Kinase | 1 | 2012 | 5 | 0.100 |
Why?
| Piperazines | 1 | 2013 | 117 | 0.100 |
Why?
| Human Umbilical Vein Endothelial Cells | 1 | 2013 | 90 | 0.100 |
Why?
| Platelet Activation | 1 | 2012 | 46 | 0.100 |
Why?
| Adenosine | 1 | 2012 | 69 | 0.100 |
Why?
| Erucic Acids | 1 | 2012 | 1 | 0.100 |
Why?
| Purinergic P2Y Receptor Antagonists | 1 | 2012 | 29 | 0.100 |
Why?
| Regeneration | 1 | 2013 | 72 | 0.100 |
Why?
| Neurites | 1 | 2012 | 13 | 0.100 |
Why?
| Neurogenesis | 1 | 2012 | 27 | 0.100 |
Why?
| ATP-Binding Cassette Transporters | 1 | 2012 | 34 | 0.100 |
Why?
| Hepatocytes | 1 | 2013 | 182 | 0.100 |
Why?
| Axons | 1 | 2012 | 45 | 0.100 |
Why?
| Autophagy | 1 | 2013 | 169 | 0.100 |
Why?
| Insulin-Secreting Cells | 1 | 2012 | 23 | 0.100 |
Why?
| Glucose Intolerance | 1 | 2012 | 27 | 0.100 |
Why?
| Protein Phosphatase 1 | 1 | 2011 | 7 | 0.100 |
Why?
| Protein Binding | 4 | 2016 | 660 | 0.100 |
Why?
| RNA Precursors | 1 | 2011 | 9 | 0.100 |
Why?
| Pyridinium Compounds | 1 | 2011 | 19 | 0.100 |
Why?
| Hematocrit | 1 | 2011 | 44 | 0.100 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2013 | 202 | 0.100 |
Why?
| Adipose Tissue, Brown | 1 | 2012 | 40 | 0.100 |
Why?
| Muscle, Smooth, Vascular | 1 | 2012 | 130 | 0.100 |
Why?
| Fibroblasts | 2 | 2012 | 345 | 0.100 |
Why?
| Erythrocyte Transfusion | 1 | 2011 | 46 | 0.100 |
Why?
| Integrins | 1 | 2011 | 31 | 0.100 |
Why?
| Alternative Splicing | 1 | 2011 | 56 | 0.100 |
Why?
| Anemia | 1 | 2011 | 68 | 0.100 |
Why?
| Heme Oxygenase-1 | 1 | 2011 | 19 | 0.100 |
Why?
| Phenotype | 4 | 2015 | 729 | 0.100 |
Why?
| Caveolin 1 | 1 | 2011 | 21 | 0.100 |
Why?
| Platelet Aggregation Inhibitors | 1 | 2012 | 172 | 0.090 |
Why?
| Catechin | 1 | 2011 | 28 | 0.090 |
Why?
| Lipoproteins, LDL | 1 | 2012 | 170 | 0.090 |
Why?
| Eicosapentaenoic Acid | 1 | 2010 | 20 | 0.090 |
Why?
| Docosahexaenoic Acids | 1 | 2010 | 27 | 0.090 |
Why?
| alpha Karyopherins | 1 | 2010 | 1 | 0.090 |
Why?
| Phospholipase D | 1 | 2010 | 6 | 0.090 |
Why?
| Exercise | 1 | 2015 | 495 | 0.090 |
Why?
| Active Transport, Cell Nucleus | 1 | 2010 | 34 | 0.090 |
Why?
| Amidines | 1 | 2010 | 8 | 0.090 |
Why?
| Liposomes | 1 | 2010 | 48 | 0.090 |
Why?
| Group V Phospholipases A2 | 1 | 2010 | 1 | 0.090 |
Why?
| Sequence Alignment | 1 | 2010 | 121 | 0.090 |
Why?
| Membrane Lipids | 1 | 2010 | 13 | 0.090 |
Why?
| rho GTP-Binding Proteins | 1 | 2010 | 6 | 0.090 |
Why?
| Macrophage Activation | 1 | 2010 | 25 | 0.090 |
Why?
| Cholesterol, LDL | 1 | 2010 | 34 | 0.090 |
Why?
| Cerebellum | 1 | 2011 | 135 | 0.090 |
Why?
| Colonic Neoplasms | 1 | 2011 | 161 | 0.090 |
Why?
| Mice, Inbred BALB C | 1 | 2010 | 304 | 0.090 |
Why?
| Inflammation | 1 | 2014 | 604 | 0.090 |
Why?
| Recombinant Fusion Proteins | 1 | 2010 | 181 | 0.090 |
Why?
| Kinetics | 3 | 2016 | 623 | 0.080 |
Why?
| Cardiovascular Diseases | 1 | 2015 | 440 | 0.080 |
Why?
| Aging | 1 | 2014 | 687 | 0.080 |
Why?
| Hydrolysis | 3 | 2016 | 63 | 0.080 |
Why?
| Astrocytes | 1 | 2011 | 145 | 0.080 |
Why?
| Boronic Acids | 1 | 2010 | 182 | 0.080 |
Why?
| Models, Molecular | 3 | 2016 | 338 | 0.080 |
Why?
| Amino Acid Sequence | 1 | 2010 | 585 | 0.080 |
Why?
| Magnetic Resonance Spectroscopy | 3 | 2015 | 244 | 0.080 |
Why?
| Catalysis | 3 | 2014 | 88 | 0.080 |
Why?
| Colorectal Neoplasms | 1 | 2012 | 236 | 0.080 |
Why?
| Neurons | 1 | 2012 | 460 | 0.080 |
Why?
| Interleukin-6 | 1 | 2010 | 264 | 0.080 |
Why?
| Substrate Specificity | 3 | 2014 | 194 | 0.080 |
Why?
| RNA, Small Interfering | 3 | 2015 | 215 | 0.080 |
Why?
| Protein Structure, Tertiary | 3 | 2016 | 253 | 0.080 |
Why?
| Mice, Transgenic | 3 | 2015 | 555 | 0.080 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2010 | 388 | 0.080 |
Why?
| Rats | 4 | 2016 | 3305 | 0.080 |
Why?
| CHO Cells | 3 | 2013 | 120 | 0.080 |
Why?
| Hematopoietic Stem Cell Transplantation | 1 | 2013 | 565 | 0.080 |
Why?
| Cricetinae | 3 | 2013 | 192 | 0.080 |
Why?
| Phosphorylation | 3 | 2015 | 535 | 0.070 |
Why?
| Cell Differentiation | 1 | 2010 | 651 | 0.070 |
Why?
| Structure-Activity Relationship | 3 | 2014 | 395 | 0.070 |
Why?
| Adipose Tissue | 3 | 2013 | 187 | 0.070 |
Why?
| Glutathione Disulfide | 2 | 2015 | 41 | 0.070 |
Why?
| Appalachian Region | 2 | 2016 | 10 | 0.060 |
Why?
| Receptors, Lysophosphatidic Acid | 2 | 2016 | 4 | 0.060 |
Why?
| Disease Models, Animal | 3 | 2015 | 1455 | 0.060 |
Why?
| Crystallography, X-Ray | 2 | 2016 | 147 | 0.060 |
Why?
| Chromatography, High Pressure Liquid | 2 | 2017 | 349 | 0.060 |
Why?
| Catalytic Domain | 2 | 2014 | 57 | 0.060 |
Why?
| Random Allocation | 2 | 2016 | 281 | 0.060 |
Why?
| Spectrometry, Mass, Electrospray Ionization | 2 | 2013 | 62 | 0.060 |
Why?
| Gene Expression Regulation | 3 | 2012 | 976 | 0.050 |
Why?
| Base Sequence | 2 | 2015 | 643 | 0.050 |
Why?
| Receptors, Lysosphingolipid | 2 | 2013 | 5 | 0.050 |
Why?
| Polymerase Chain Reaction | 2 | 2015 | 453 | 0.050 |
Why?
| Glucose Tolerance Test | 2 | 2013 | 57 | 0.050 |
Why?
| NAD(P)H Dehydrogenase (Quinone) | 2 | 2013 | 14 | 0.050 |
Why?
| Phosphatidylinositol 4,5-Diphosphate | 2 | 2013 | 10 | 0.050 |
Why?
| Cricetulus | 2 | 2013 | 97 | 0.050 |
Why?
| Thiazolidinediones | 2 | 2015 | 82 | 0.050 |
Why?
| Recombinant Proteins | 2 | 2015 | 486 | 0.050 |
Why?
| Mass Spectrometry | 2 | 2013 | 306 | 0.050 |
Why?
| Platelet Aggregation | 2 | 2012 | 71 | 0.050 |
Why?
| Enzyme Activation | 2 | 2012 | 276 | 0.050 |
Why?
| Genotype | 2 | 2014 | 537 | 0.050 |
Why?
| Female | 7 | 2018 | 26472 | 0.050 |
Why?
| Lipids | 2 | 2014 | 147 | 0.050 |
Why?
| Staphylococcus aureus | 2 | 2015 | 326 | 0.050 |
Why?
| Time Factors | 3 | 2012 | 2903 | 0.050 |
Why?
| Glycoproteins | 2 | 2013 | 115 | 0.050 |
Why?
| Fatty Acids | 2 | 2012 | 146 | 0.050 |
Why?
| Blood Glucose | 2 | 2013 | 439 | 0.040 |
Why?
| Cytokines | 2 | 2014 | 612 | 0.040 |
Why?
| Swine | 2 | 2011 | 393 | 0.040 |
Why?
| Apoptosis | 2 | 2015 | 1101 | 0.040 |
Why?
| NF-kappa B | 2 | 2010 | 314 | 0.040 |
Why?
| Acrylates | 1 | 2017 | 3 | 0.040 |
Why?
| Coal | 1 | 2016 | 1 | 0.040 |
Why?
| Glycosylation | 1 | 2016 | 100 | 0.030 |
Why?
| Taurochenodeoxycholic Acid | 1 | 2016 | 1 | 0.030 |
Why?
| Hydroxycholesterols | 1 | 2016 | 9 | 0.030 |
Why?
| Phosphatidylcholines | 1 | 2016 | 25 | 0.030 |
Why?
| Food-Drug Interactions | 1 | 2016 | 14 | 0.030 |
Why?
| Molecular Conformation | 1 | 2016 | 67 | 0.030 |
Why?
| Enzyme Induction | 1 | 2016 | 80 | 0.030 |
Why?
| Risk Factors | 2 | 2015 | 3613 | 0.030 |
Why?
| Debridement | 1 | 2015 | 46 | 0.030 |
Why?
| Leukocyte Count | 1 | 2015 | 70 | 0.030 |
Why?
| Drug Delivery Systems | 1 | 2017 | 138 | 0.030 |
Why?
| Transaldolase | 1 | 2015 | 1 | 0.030 |
Why?
| Systole | 1 | 2015 | 68 | 0.030 |
Why?
| Uridine Monophosphate | 1 | 2015 | 4 | 0.030 |
Why?
| Heme | 1 | 2015 | 21 | 0.030 |
Why?
| Lipid Peroxidation | 1 | 2015 | 100 | 0.030 |
Why?
| Threonine | 1 | 2015 | 16 | 0.030 |
Why?
| Diet, Fat-Restricted | 1 | 2015 | 11 | 0.030 |
Why?
| Polyethylene Glycols | 1 | 2015 | 93 | 0.030 |
Why?
| Open Reading Frames | 1 | 2015 | 55 | 0.030 |
Why?
| Myocardial Contraction | 1 | 2015 | 105 | 0.030 |
Why?
| Bronchi | 1 | 2015 | 43 | 0.030 |
Why?
| Administration, Oral | 1 | 2016 | 426 | 0.030 |
Why?
| Gene Silencing | 1 | 2015 | 119 | 0.030 |
Why?
| Imidazoles | 1 | 2015 | 119 | 0.030 |
Why?
| Hep G2 Cells | 1 | 2014 | 36 | 0.030 |
Why?
| Ventricular Dysfunction, Left | 1 | 2015 | 91 | 0.030 |
Why?
| Brachiocephalic Trunk | 1 | 2014 | 6 | 0.030 |
Why?
| Coal Mining | 1 | 2014 | 4 | 0.030 |
Why?
| Protein Structure, Quaternary | 1 | 2014 | 26 | 0.030 |
Why?
| Protein Engineering | 1 | 2014 | 18 | 0.030 |
Why?
| Nitrophenols | 1 | 2014 | 16 | 0.030 |
Why?
| Amino Acid Motifs | 1 | 2014 | 56 | 0.030 |
Why?
| Biocatalysis | 1 | 2014 | 15 | 0.030 |
Why?
| Receptor, TIE-2 | 1 | 2014 | 16 | 0.030 |
Why?
| 3T3-L1 Cells | 1 | 2013 | 13 | 0.030 |
Why?
| Naphthols | 1 | 2013 | 9 | 0.030 |
Why?
| Carbohydrates | 1 | 2014 | 40 | 0.030 |
Why?
| Integrases | 1 | 2014 | 43 | 0.030 |
Why?
| Cyclization | 1 | 2013 | 5 | 0.030 |
Why?
| Transgenes | 1 | 2014 | 55 | 0.030 |
Why?
| Glutarates | 1 | 2013 | 6 | 0.030 |
Why?
| Escherichia coli | 1 | 2015 | 186 | 0.030 |
Why?
| Stereoisomerism | 1 | 2013 | 104 | 0.030 |
Why?
| Micromonospora | 1 | 2013 | 1 | 0.030 |
Why?
| Enediynes | 1 | 2013 | 1 | 0.030 |
Why?
| Mice, Inbred NOD | 1 | 2013 | 96 | 0.030 |
Why?
| Salmonella enterica | 1 | 2013 | 16 | 0.030 |
Why?
| DNA Primers | 1 | 2013 | 207 | 0.030 |
Why?
| Motor Activity | 1 | 2015 | 229 | 0.030 |
Why?
| Talin | 1 | 2013 | 3 | 0.030 |
Why?
| Stress, Physiological | 1 | 2014 | 170 | 0.030 |
Why?
| Integrin beta Chains | 1 | 2013 | 14 | 0.030 |
Why?
| Chemotactic Factors | 1 | 2013 | 5 | 0.030 |
Why?
| Cathelicidins | 1 | 2013 | 1 | 0.030 |
Why?
| beta-Defensins | 1 | 2013 | 4 | 0.030 |
Why?
| Superoxide Dismutase | 1 | 2013 | 113 | 0.030 |
Why?
| Regenerative Medicine | 1 | 2013 | 9 | 0.030 |
Why?
| Epithelial Cells | 1 | 2015 | 209 | 0.030 |
Why?
| Cell Growth Processes | 1 | 2013 | 22 | 0.030 |
Why?
| Caspases | 1 | 2013 | 104 | 0.030 |
Why?
| HSP90 Heat-Shock Proteins | 1 | 2013 | 50 | 0.030 |
Why?
| Receptors, CXCR4 | 1 | 2013 | 28 | 0.030 |
Why?
| Receptors, Purinergic P2Y | 1 | 2012 | 3 | 0.030 |
Why?
| Drug Screening Assays, Antitumor | 1 | 2013 | 136 | 0.030 |
Why?
| Aorta | 1 | 2014 | 161 | 0.030 |
Why?
| Methionine | 1 | 2014 | 135 | 0.030 |
Why?
| Epoprostenol | 1 | 2012 | 20 | 0.030 |
Why?
| Adenosine Diphosphate | 1 | 2012 | 21 | 0.030 |
Why?
| Isotope Labeling | 1 | 2013 | 53 | 0.030 |
Why?
| Neointima | 1 | 2012 | 5 | 0.030 |
Why?
| Chemokine CXCL12 | 1 | 2013 | 32 | 0.030 |
Why?
| Diet, Atherogenic | 1 | 2012 | 8 | 0.030 |
Why?
| Mice, Obese | 1 | 2012 | 21 | 0.030 |
Why?
| Antigens, CD34 | 1 | 2013 | 66 | 0.030 |
Why?
| rho-Associated Kinases | 1 | 2012 | 20 | 0.030 |
Why?
| Microfilament Proteins | 1 | 2012 | 43 | 0.030 |
Why?
| Staphylococcal Infections | 1 | 2015 | 268 | 0.030 |
Why?
| Mice, Mutant Strains | 1 | 2012 | 71 | 0.030 |
Why?
| Cell Hypoxia | 1 | 2013 | 82 | 0.030 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2013 | 197 | 0.030 |
Why?
| Cross-Sectional Studies | 1 | 2018 | 1557 | 0.030 |
Why?
| Carotid Artery, Common | 1 | 2012 | 44 | 0.030 |
Why?
| Cyclic AMP | 1 | 2012 | 90 | 0.030 |
Why?
| Hyperplasia | 1 | 2012 | 96 | 0.030 |
Why?
| Cell Adhesion Molecules | 1 | 2012 | 88 | 0.030 |
Why?
| Gene Expression Regulation, Bacterial | 1 | 2014 | 191 | 0.030 |
Why?
| Lysine | 1 | 2013 | 89 | 0.030 |
Why?
| Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 83 | 0.030 |
Why?
| Gene Expression | 1 | 2015 | 609 | 0.030 |
Why?
| Embryonic Stem Cells | 1 | 2012 | 15 | 0.030 |
Why?
| Adipokines | 1 | 2012 | 11 | 0.030 |
Why?
| Neoplasm Metastasis | 1 | 2013 | 231 | 0.030 |
Why?
| Insulinoma | 1 | 2012 | 7 | 0.030 |
Why?
| Microbial Sensitivity Tests | 1 | 2013 | 269 | 0.030 |
Why?
| Saccharomyces cerevisiae | 1 | 2013 | 190 | 0.030 |
Why?
| Paxillin | 1 | 2012 | 6 | 0.030 |
Why?
| Subcutaneous Fat | 1 | 2012 | 18 | 0.030 |
Why?
| Oncogene Protein v-akt | 1 | 2012 | 10 | 0.030 |
Why?
| Embryo, Mammalian | 1 | 2012 | 66 | 0.030 |
Why?
| Neoplasm Invasiveness | 1 | 2013 | 267 | 0.030 |
Why?
| Phosphoproteins | 1 | 2012 | 107 | 0.030 |
Why?
| Injections, Intraperitoneal | 1 | 2012 | 54 | 0.030 |
Why?
| Blood Vessels | 1 | 2012 | 72 | 0.030 |
Why?
| Focal Adhesion Kinase 1 | 1 | 2012 | 15 | 0.030 |
Why?
| Lyases | 1 | 2011 | 2 | 0.030 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2012 | 157 | 0.030 |
Why?
| Lipogenesis | 1 | 2012 | 29 | 0.030 |
Why?
| Dyslipidemias | 1 | 2012 | 36 | 0.030 |
Why?
| Bone and Bones | 1 | 2015 | 469 | 0.030 |
Why?
| Proto-Oncogene Proteins c-met | 1 | 2012 | 20 | 0.030 |
Why?
| Lipoproteins, HDL | 1 | 2011 | 18 | 0.030 |
Why?
| Disease Susceptibility | 1 | 2012 | 89 | 0.030 |
Why?
| Transfection | 1 | 2012 | 354 | 0.030 |
Why?
| Vinculin | 1 | 2011 | 3 | 0.030 |
Why?
| Blood Preservation | 1 | 2011 | 26 | 0.030 |
Why?
| HCT116 Cells | 1 | 2011 | 22 | 0.020 |
Why?
| Lymphocytes | 1 | 2012 | 152 | 0.020 |
Why?
| Myocardial Ischemia | 1 | 2013 | 120 | 0.020 |
Why?
| Prospective Studies | 1 | 2018 | 2364 | 0.020 |
Why?
| Gene Knockdown Techniques | 1 | 2012 | 106 | 0.020 |
Why?
| Ion Channels | 1 | 2012 | 72 | 0.020 |
Why?
| Antigens, CD | 1 | 2013 | 219 | 0.020 |
Why?
| Exons | 1 | 2011 | 95 | 0.020 |
Why?
| Fibronectins | 1 | 2011 | 39 | 0.020 |
Why?
| Mitochondrial Proteins | 1 | 2012 | 90 | 0.020 |
Why?
| Erythrocytes | 1 | 2011 | 83 | 0.020 |
Why?
| Promoter Regions, Genetic | 1 | 2014 | 475 | 0.020 |
Why?
| Cell Survival | 1 | 2013 | 600 | 0.020 |
Why?
| Caveolae | 1 | 2011 | 6 | 0.020 |
Why?
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2011 | 32 | 0.020 |
Why?
| Mice, Nude | 1 | 2012 | 252 | 0.020 |
Why?
| Xenograft Model Antitumor Assays | 1 | 2012 | 211 | 0.020 |
Why?
| Rotarod Performance Test | 1 | 2011 | 6 | 0.020 |
Why?
| Asthma | 1 | 2015 | 281 | 0.020 |
Why?
| Bilirubin | 1 | 2011 | 40 | 0.020 |
Why?
| Cell Adhesion | 1 | 2011 | 158 | 0.020 |
Why?
| Borohydrides | 1 | 2010 | 1 | 0.020 |
Why?
| Neuroprostanes | 1 | 2010 | 1 | 0.020 |
Why?
| Motor Skills | 1 | 2011 | 25 | 0.020 |
Why?
| Cyclopentanes | 1 | 2010 | 10 | 0.020 |
Why?
| Organ Culture Techniques | 1 | 2011 | 48 | 0.020 |
Why?
| Cytoprotection | 1 | 2010 | 35 | 0.020 |
Why?
| In Situ Nick-End Labeling | 1 | 2011 | 57 | 0.020 |
Why?
| RNA-Binding Proteins | 1 | 2011 | 123 | 0.020 |
Why?
| Superoxides | 1 | 2010 | 46 | 0.020 |
Why?
| Fatty Liver | 1 | 2012 | 127 | 0.020 |
Why?
| Dose-Response Relationship, Drug | 1 | 2014 | 1376 | 0.020 |
Why?
| Binding Sites | 1 | 2011 | 374 | 0.020 |
Why?
| Cell Count | 1 | 2011 | 147 | 0.020 |
Why?
| Lymph Nodes | 1 | 2012 | 260 | 0.020 |
Why?
| Down-Regulation | 1 | 2012 | 348 | 0.020 |
Why?
| Phosphodiesterase I | 1 | 2010 | 1 | 0.020 |
Why?
| Cell Membrane | 1 | 2011 | 248 | 0.020 |
Why?
| Pyrophosphatases | 1 | 2010 | 13 | 0.020 |
Why?
| Oxadiazoles | 1 | 2010 | 10 | 0.020 |
Why?
| Multienzyme Complexes | 1 | 2010 | 34 | 0.020 |
Why?
| Cell Line | 1 | 2013 | 1000 | 0.020 |
Why?
| Lipolysis | 1 | 2010 | 10 | 0.020 |
Why?
| Inhibitory Concentration 50 | 1 | 2010 | 76 | 0.020 |
Why?
| COS Cells | 1 | 2010 | 74 | 0.020 |
Why?
| Albumins | 1 | 2010 | 31 | 0.020 |
Why?
| Drug Evaluation, Preclinical | 1 | 2010 | 144 | 0.020 |
Why?
| Oxidation-Reduction | 1 | 2010 | 322 | 0.020 |
Why?
| Risk Assessment | 1 | 2014 | 1259 | 0.020 |
Why?
| Endothelium, Vascular | 1 | 2011 | 252 | 0.020 |
Why?
| Protein Transport | 1 | 2010 | 180 | 0.020 |
Why?
| Pancreatic Neoplasms | 1 | 2012 | 208 | 0.020 |
Why?
| Liver Neoplasms | 1 | 2012 | 326 | 0.020 |
Why?
| Immunohistochemistry | 1 | 2011 | 973 | 0.020 |
Why?
| Lung Neoplasms | 1 | 2013 | 606 | 0.020 |
Why?
| Aged | 1 | 2011 | 9310 | 0.010 |
Why?
| Middle Aged | 1 | 2011 | 12069 | 0.010 |
Why?
| Adult | 1 | 2011 | 13236 | 0.010 |
Why?
|
|
Morris's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|